Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash from Financing Activities for 6 consecutive years, with -$850000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Cash from Financing Activities fell 1077.01% to -$850000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $94.4 million, a 60029.94% increase, with the full-year FY2024 number at $130000.0, down 60.12% from a year prior.
  • Cash from Financing Activities was -$850000.0 for Q2 2025 at Whitehawk Therapeutics, down from $95.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $141.7 million in Q3 2021 to a low of -$850000.0 in Q2 2025.
  • A 5-year average of $18.2 million and a median of $70279.0 in 2021 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 952110.0% in 2025; the steepest drop was 1077.01% in 2025.
  • Whitehawk Therapeutics' Cash from Financing Activities stood at $88000.0 in 2021, then tumbled by 221.59% to -$107000.0 in 2022, then surged by 174.77% to $80000.0 in 2023, then plummeted by 33.75% to $53000.0 in 2024, then tumbled by 1703.77% to -$850000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Cash from Financing Activities are -$850000.0 (Q2 2025), $95.2 million (Q1 2025), and $53000.0 (Q4 2024).